Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population

Therapeutic Drug Monitoring

Volumn 21, Issue 2, 1999, Pages 224-230

  Falcão, Amilcar Celta ^b   De Almeida, Anabela Maduro ^c   Leitão, Fátima ^c   Santos, Jorge ^a   Sales, Francisco ^a   Caramona, Maria Margarida ^c  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c NONE

Author keywords

Bayesian approach; Carbamazepine; Pharmacokinetics; Prediction error

Indexed keywords

CARBAMAZEPINE;

ACCURACY; ADULT; ANTICONVULSANT THERAPY; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTICONVULSANTS; BAYES THEOREM; CARBAMAZEPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PORTUGAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 0032898116     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199904000-00014     Document Type: Article

References (39)

1. Shorvon SD. Epidemiology, classification, natural history and genetic of epilepsy. Lancet 1990;336:93-6.
2. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 18:168-75.
3. Bertilsson L, Tomson T. Clinical pharmacokinetics and effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 1986;11:177-98.
4. Thomson AH, Brodie MJ. Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 1992;23:216-30.
5. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit 1986;8:305-17.
6. Brodie MJ. Drug interaction in epilepsy. Epilepsia 1992;33:S13-22.
7. Spina E, Pisani F, Perruca E. Clinically significant pharmacokinetic drug interaction with carbamazepine. Clin Pharmacokinet 1996;31:198-214.
8. Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet 1996;31:470-93.
9. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979;26:294-305.
10. Tanigawara Y, Yano I, Kawakatsu K, et al. Predictive performance of Bayesian analysis: Effects of blood sampling time, population parameters, and pharmacostatistical model. J Pharmacokinet Biopharm 1994;22:59-71.
11. El Battah A, Beglia S, Alric R. Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring. Ther Drug Monit 1995;17:348-55.
12. Almeida AM, Canas N, Costa IM, et al. PKBase - A database developed for populational pharmacokinetic studies: Concept and application. Ther Drug Monit 1997;19:548 .
13. Alonso Gonzalez AC, Garcia Sanchez MJ, Dominguez-Gil Hurle A. Contribution of serum level monitoring in the individualization of carbamazepine dosage regimens. Int J Clin Pharmacol Ther Toxicol 1988;26:409-12.
14. Rosner B, ed. Fundamentals of biostatistics, 4th ed. Belmont, CA: Duxbury, 1995:34.
15. Sánchez A, Durán JA, Serrano JS. Steady-state carbamazepine plasma concentration-dose ratios in epileptic patients. Clin Pharmacokinet 1986;11:411-4.
16. Lui H, Delgado MR. Influence of sex, age, weight and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit 1994;16:469-76.
17. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine, and felbamate. Clin Pharmacokinet 1995;29:341-69.
18. Bernus I, Dickinson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients. Drugs Aging 1997;10:278-89.
19. Kleijn E, Schobben F, Vree TB. Clinical pharmacokinetics of antiepileptic drugs. Drug Intell Clin Pharm 1980;14:674-85.
20. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-13.
21. Bryson SM, Al-Lanqawi Y, Kelman AW, et al. Comparison of Bayesian forecasting technique with a new method for estimating phenytoin dose requirements. Ther Drug Monit 1988;10:80-4.
22. Garcia MJ, Alonso AC, Maza A, et al. Comparison of methods of carbamazepine dosage, individualization in epileptic patients. J Clin Pharm Ther 1988;13:375-80.
23. Killilea T, Coleman R, Ludden T, et al. Bayesian regression analysis of non-steady-state phenytoin concentrations: Evaluation of predictive performance. Ther Drug Monit 1989;11:455-62.
24. Murphy MG, Peck CC, Merenstein GB, et al. An evaluation of Bayesian microcomputer predictions of theophylline concentrations in newborn infants. Ther Drug Monit 1990;12:47-53.
25. Hudson SA, Farquhar DL, Thompson D, et al. Phenytoin dosage individualization - five methods compared in the elderly. J Clin Pharm Ther 1990;15:25-34.
26. Vázquez Rodríguez A, Santos Buelga D, Alonso González AC, et al. Comparison of methods for the prediction of phenytoin concentrations. J. Clin Pharm Ther 1991;16:55-62.
27. Scheyer RD, Cramer JA, Mattson RH. A pharmacodynamic approach to the estimate of carbamazepine autoinduction. J Pharm Sci 1994;83:491-4.
28. Ratnajara N, Hjelm M. Prediction of free levels of phenytoin and carbamazepine in patients comedicated with valproic acid. Ther Drug Monit 1995;17:327-32.
29. Kodama Y, Kuranari M, Kodama H, et al. Evaluation of equations for unbound serum concentration prediction of carbamazepine and carbamzepine-10,11-epoxide in polytherapy pediatric patients with epilepsy. J Pharm Sci 1995;84:835-9.
30. Gaulier JM, Boulieu R, Fischer C, et al. Prediction of carbamazepine concentrations using a Bayesian program (PKS System, Abbott Laboratories): A retrospective evaluation in an outpatient population. J Pharm Pharmacol 1997;49:734-6.
31. Scheuer ML, Pedley TA. The evaluation and treatment of seizures. N Engl J Med 1990;323:1468-74.
32. Pugh CB, Garnett WR. Therapy review: Current issues in the treatment of epilepsy. Clin Pharmacol 1991;10:335-58.
33. Westenberg HGM, Kleijn E, Oei TT, et al. Kinetic of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Clin Pharmacol Ther 1978;23:320-8.
34. Wong YY, Ludden TM, Bell RD. Effect of erythromicin on carbamazepine kinetics. Clin Pharmacol Ther 1983;33:460-4.
35. Miller R, Ludden TM. Bioavailability of controlled release carbamazepine estimated by mixed effect modelling. Eur J Clin Pharmacol 1993;44:231-5.
36. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens: Pharmacokinetic data. In: Hardman JG, Linbird LE, Molinoff PB, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York:McGraw-Hill, 1995.
37. Yukawa E. Population-based investigation of carbamazepine relative clearance using routine clinical pharmacokinetic data in Japan. A multiple peak approach feasibility study for pharmacokinetic screening. Clin Drug Invest 1995;10:29-39.
38. Buffington DE, Lampasona V, Chandler MHH. Computers in pharmacokinetics. Clin Pharmacokinet 1993;25:205-16.
39. Tomson T, Tybring G, Bertilsson L. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther 1983;33:58-65.